Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 04:00PM ET
0.1052
Dollar change
+0.0010
Percentage change
0.96
%
Index- P/E- EPS (ttm)-1.74 Insider Own10.65% Shs Outstand36.03M Perf Week1.64%
Market Cap3.79M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float31.65M Perf Month-35.58%
Income-45.22M PEG- EPS next Q- Inst Own6.36% Short Float2.08% Perf Quarter-65.83%
Sales6.99M P/S0.54 EPS this Y- Inst Trans-13.79% Short Ratio0.09 Perf Half Y-73.03%
Book/sh1.20 P/B0.09 EPS next Y- ROA-44.80% Short Interest0.66M Perf Year-85.78%
Cash/sh0.07 P/C1.59 EPS next 5Y- ROE-81.57% 52W Range0.07 - 0.88 Perf YTD-76.11%
Dividend Est.- P/FCF- EPS past 5Y22.72% ROI-102.74% 52W High-88.11% Beta-0.16
Dividend TTM- Quick Ratio0.47 Sales past 5Y325.62% Gross Margin-59.25% 52W Low50.50% ATR (14)0.03
Dividend Ex-Date- Current Ratio0.47 EPS Y/Y TTM-2.40% Oper. Margin-639.57% RSI (14)40.60 Volatility31.40% 22.76%
Employees84 Debt/Eq0.45 Sales Y/Y TTM9.58% Profit Margin-646.44% Recom1.00 Target Price8.00
Option/ShortYes / Yes LT Debt/Eq0.40 EPS Q/Q56.43% Payout- Rel Volume2.65 Prev Close0.10
Sales Surprise- EPS Surprise- Sales Q/Q5966.34% EarningsApr 29 BMO Avg Volume7.59M Price0.11
SMA20-30.65% SMA50-33.41% SMA200-70.92% Trades Volume20,108,937 Change0.96%
May-20-24 08:00AM
May-16-24 04:15PM
08:00AM
May-15-24 08:00AM
May-14-24 01:55PM
07:15AM Loading…
07:15AM
May-07-24 08:30AM
Apr-29-24 08:00AM
Apr-23-24 05:27AM
Apr-22-24 05:00PM
Mar-19-24 08:30AM
Mar-14-24 08:30AM
Mar-12-24 05:00PM
Mar-08-24 12:20AM
Mar-07-24 04:18PM
08:30AM Loading…
08:30AM
Feb-06-24 08:00AM
Feb-01-24 08:00AM
Jan-30-24 08:00AM
Jan-25-24 08:30AM
Jan-16-24 08:30AM
Jan-08-24 08:30AM
Jan-03-24 08:30AM
Dec-21-23 08:30AM
Dec-18-23 08:30AM
Dec-12-23 08:30AM
Nov-20-23 04:05PM
Oct-09-23 08:26AM
Aug-24-23 08:24AM
08:24AM
04:05PM Loading…
Aug-14-23 04:05PM
May-19-23 10:46AM
May-15-23 04:05PM
Apr-11-23 08:23AM
Mar-31-23 04:05PM
Dec-12-22 09:02AM
Nov-14-22 04:01PM
Oct-21-22 08:00AM
Aug-23-22 07:30AM
Aug-17-22 10:55AM
10:55AM
Aug-10-22 04:05PM
Jun-13-22 08:00AM
May-18-22 12:48PM
May-16-22 04:44PM
May-10-22 08:00AM
Scorpius Holdings, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.